Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss

The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.

Eisai announced a deal with BlissBio for the Chinese company's HER2-directed ADC • Source: Shutterstock

With the success of AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (fam-trastuzumab daruxtecan-nxki), a number of drug makers are hoping to get in on the HER2 game as well, in some cases looking to companies in China developing HER2-targeting antibody-drug conjugates (ADC). Japanese drug maker Eisai Co., Ltd. is the latest firm to take that route with a development partnership centered on Bliss Biopharmaceutical Co. Ltd.’s Phase I/II ADC candidate.

Hangzhou, China-based BlissBio said 7 May that it had signed a clinical trial collaboration agreement with Eisai with an option for strategic collaboration for BB-1701, its eribulin payload-based ADC against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

More from Business

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By 

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.